University of Maryland, Center for Vaccine Development, Trials

University of Maryland, Center for Vaccine Development,	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Lyke, Kirsten E

NCT04889209: Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

Completed

1/2

867

Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1

National Institute of Allergy and Infectious Diseases (NIAID)

COVID-19

06/23

NCT03718130: Combination HTNV and PUUV DNA Vaccine

Active, not recruiting

Hantann virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID), HTNV vaccine using TDS ID, Hantann virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM), HTNV vaccine using TDS IM, Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID), PUUV vaccine using TDS ID, Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM), PUUV vaccine using the TDS IM, Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID), HTNV/PUUV vaccines using the TDS ID, Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM), HTNV/PUUV vaccines using the TDS IM

U.S. Army Medical Research and Development Command

Hantaan Virus Disease, Puumala Virus

12/22

04/23

NCT05604521: A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI

Terminated

PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline, Placebo

Sanaria Inc., University of Maryland, Baltimore, National Institute of Allergy and Infectious Diseases (NIAID)

Malaria, Malaria,Falciparum

09/23

DHIM-4, NCT05268302: Dengue 4 Human Infection Model (Dengue CVD 11000; )

Completed

Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose, Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Medium Dose, Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - High Dose

University of Maryland, Baltimore, Medical Technology Enterprise Consortium (MTEC)

Dengue

01/24



	Diseases Companies Products Productz Mechanisms of Action Sites